Progression in the evaluation criteria for therapeutic efficacy of colorectal cancer: challenges and advances

doi:10.3877/cma.j.issn.2095-3224.2018.01.003

Abstract

Abstract:

Since anti-cancer therapeutic methods is progressing, response evaluated criteria is subsequently upstated. From WHO and RECIST criteria for chemotherapy, CHOI criteria and CT morphology for anti-angiogenesis therapy, to the newest criteria for immunotherapy. Each criteria was raised and established during the challenge to the original one. Here, we summarized the progression of response evaluation criteria according to different anti-cancer therapeutic regimen.

Key words: Colorectal neoplasms, Therapy, Progression, Anti-angiogenesis therapy, Immunotherapy

Xiujuan Qu, Yunpeng Liu. Progression in the evaluation criteria for therapeutic efficacy of colorectal cancer: challenges and advances[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 12-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.01.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/12

References 16

[1]	Litière S, Collette S, de Vries EG, et al. RECIST–learning from the past to build the future [J]. Nat Rev Clin Oncol, 2017, 14(3): 187-192.
[2]	Ma B, King AD, Leung L, et al. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria [J]. Ann Oncol, 2017 Mar 30. [Epub ahead of print]
[3]	Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development [J]. Nature Reviews Drug Discovery, 2007, 6(9): 734-745.
[4]	Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings [J]. American Journal of Roentgenology, 2004, 183(6): 1619-1628.
[5]	Benjamin RS, Choi H, Macapinlac HA, et al. We Should Desist Using RECIST, at Least in GIST [J]. Journal of Clinical Oncology, 2007, 25(13): 1760-1764.
[6]	Blanke CD, Demetri GD, Mehren MV, et al. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT [J]. Journal of Clinical Oncology, 2008, 26(4): 620-625.
[7]	Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[C] //Seminars in liver disease. © Thieme Medical Publishers, 2010, 30(01): 52-60.
[8]	Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria [J]. Clinical cancer research, 2009, 15(23): 7412-7420.
[9]	Hoos A. Evolution of end points for cancer immunotherapy trials [J]. Annals of Oncology, 2012, 23 (Suppl 8): viii47-52.
[10]	Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107 [J]. Journal of Clinical Oncology, 2008, 26(2): 183-189.
[11]	Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases [J]. JAMA, 2009, 302(21): 2338-2344.
[12]	Ng CS, Charnsangavej C, Wei W, et al. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy [J]. American Journal of Roentgenology, 2011, 196(3): 569-576.
[13]	Mehta S, Hughes NP, Buffa FM, et al. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles [J]. J Natl Cancer Inst Monogr, 2011, 2011(43): 71-74.
[14]	Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab [J]. Journal of Clinical Oncology, 2016, 34(13): 1510-1517.
[15]	Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? [J]. Ecancer medical science, 2015, 9: 604.
[16]	Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J]. Lancet Oncol, 2017, 18(3): e143-e152.

Please choose a citation manager

Content to export